Functional (Non Ulcer) Dyspepsia Pipeline Review, H1 2019 Report Featuring Daewoong Pharmaceutical, RaQualia Pharma, & Zeria Pharmaceutical – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Functional
(Non Ulcer) Dyspepsia – Pipeline Review, H1 2019” drug
pipelines has been added to ResearchAndMarkets.com’s
offering.

Functional (Non Ulcer) Dyspepsia – Pipeline Review, H1 2019, provides
comprehensive information on the therapeutics under development for
Functional (Non Ulcer) Dyspepsia (Gastrointestinal), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide
also reviews of key players involved in therapeutic development for
Functional (Non Ulcer) Dyspepsia and features dormant and discontinued
projects. The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in Phase
III, Phase II, Phase I and Preclinical stages are 2, 1, 2 and 1
respectively. Similarly, the Universities portfolio in Discovery stages
comprises 1 molecules, respectively.

Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline guide helps
in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Functional (Non Ulcer) Dyspepsia (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Functional (Non
  Ulcer) Dyspepsia (Gastrointestinal) by companies and
  universities/research institutes based on information derived from
  company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Functional (Non
  Ulcer) Dyspepsia (Gastrointestinal) therapeutics and enlists all their
  major and minor projects.
• The pipeline guide evaluates Functional (Non Ulcer) Dyspepsia
  (Gastrointestinal) therapeutics based on mechanism of action (MoA),
  drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Functional (Non Ulcer) Dyspepsia (Gastrointestinal)

Companies Mentioned

• Daewoong Pharmaceutical Co Ltd
• RaQualia Pharma Inc
• Zeria Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/wue1cu

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Gastrointestinal
Drugs